FDA approves Icotyde for plaque psoriasis
Johnson & Johnson said the US Food and Drug Administration approved Icotyde (icotrokinra) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and in pediatric patients age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The once-daily tablet is the first approved oral peptide designed to selectively block the IL-23 receptor, giving dermatology clinicians a new non-injectable option in a category long dominated by biologics and other systemic agents. The approval was supported by the Phase 3 ICONIC program, which Johnson & Johnson said enrolled about 2,500 patients across four studies. (jnj.com)
Why it matters: For veterinary professionals, this is mainly a market and translational immunology signal rather than a practice-changing development. Icotyde’s approval highlights continued industry movement toward targeted, oral immune-modulating therapies with biologic-like efficacy, a trend worth watching for spillover into companion animal dermatology and other inflammatory indications over time. In the pivotal ICONIC-LEAD study, 65% of patients on icotrokinra achieved clear or almost clear skin at week 16 versus 8% on placebo, while PASI 90 responses were 50% versus 4%; adverse-event rates through week 16 were 49% in both groups, with nasopharyngitis and upper respiratory tract infection among the most common events. The broader competitive backdrop points the same way: Takeda recently reported Phase 3 LATITUDE data for oral TYK2 inhibitor zasocitinib showing week-16 sPGA 0/1 rates of 71.4% and 69.2% in two studies, versus roughly 11% to 13% on placebo and about 30% to 32% on apremilast, with responses continuing to improve through week 24 and durability above 90% at week 60 in one trial. (pubmed.ncbi.nlm.nih.gov; pharmashots.com)
What to watch: Next up will be launch uptake, payer positioning, and whether longer-term data and additional studies in psoriatic arthritis, ulcerative colitis, and Crohn’s disease broaden icotrokinra’s commercial and clinical role. It will also be worth watching how quickly the oral advanced-therapy field crowds in as rivals such as Takeda move toward regulatory filings for zasocitinib after strong late-stage psoriasis data. (jnj.com; pharmashots.com)